Compare Abeona Therapeutics Inc (ABEO) vs Analog Devices, Inc. (ADI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Analog Devices, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Analog Devices, Inc. trades at $388 (market cap $187.00B). The key difference: Analog Devices, Inc. is far larger — about 440.7× Abeona Therapeutics Inc's market cap, and Analog Devices, Inc. pays a 1.15% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ADI | |
|---|---|---|
Market Cap | $424.33M | $187.00B |
Sector | Health | Technology |
52-Week High | $7.45 | $445.48 |
52-Week Low | $4.17 | $225.20 |
Enterprise Value | $279.23M | $192.25B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Analog Devices (ADI) trades at $389.93, up 3.34% over the past day, with a bullish technical signal and strong institutional support. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.09 exceeding expectations. Revenue for 2025 reached $11.02 billion, with a net income margin of 26.01%, though valuation ratios like P/E of 58.03 suggest premium pricing. A dividend of $1.10 per share is scheduled for payment on June 16, 2026.
The outlook for ADI is positive, driven by robust earnings performance and analyst optimism, with a consensus price target of $474.80 implying significant upside. Risks include high valuation multiples and sensitivity to semiconductor market cycles, but strong cash flow and institutional buy-in support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →
